Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer

4 Mar 2025

Abstract excerpt

The targeting of cancer stem cells (CSCs) has proven to be an effective approach for limiting tumor progression, thus necessitating the identification of new drugs with anti-CSC activity. Through a high-throughput drug repositioning screen, we identify the antibiotic Nifuroxazide (NIF) as a potent anti-CSC compound. Utilizing a click chemistry strategy, we demonstrate that NIF is a prodrug that is specifically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40038300
DOI: 10.1038/s41467-025-57476-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancerPMID 40038300Read ↗

Emerging Combination Strategy: FANCI Inhibition Induces PARP1 Redistribution to Enhance Efficacy of PARP Inhibitors in Breast CancerSemantic proximity Read ↗

A genome‐wide RNAi screen reveals essential therapeutic targets of breast cancer stem cellsSemantic proximity Read ↗

Phenotypic High-Throughput Screening Elucidates Target Pathway in Breast Cancer Stem Cell–Like CellsSemantic proximity Read ↗

A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to ChemotherapySemantic proximity Read ↗

Selectively Targeting Breast Cancer Stem Cells By 8-Quinolinol and NiclosamideSemantic proximity Read ↗

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput ScreeningSemantic proximity Read ↗

Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.Semantic proximity Read ↗

The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancerSemantic proximity Read ↗

Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cellsSemantic proximity Read ↗

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.Semantic proximity Read ↗

Novel Dual Inhibitors of PARP and HDAC Induce Intratumoral STING-Mediated Antitumor Immunity in Triple-Negative Breast CancerSemantic proximity Read ↗

Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.